FDA Approves Redemplo (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome

Nov 19, 2025 - 04:00
 0  1
PASADENA, Calif.–(BUSINESS WIRE)–Nov. 18, 2025– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has approved Redemplo (plozasiran), a small interfering RNA (siRNA)...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0